INTRODUCTION
Vascular anomalies represent a broad spectrum of disorders produced by abnormal embryological development of blood vessels. The manifestations of these disorders may be prenatal, congenital, or postnatal. In general, they manifest with a gradual increase in size or extent, proportionally greater than the growth of the patient. 1 Vascular anomalies frequently occur as part of recognizable, pleiotropic developmental syndromes, 2 which include overgrowth syndromes. 3 CLAPO syndrome (OMIM 613089)-capillary malformation of the lower lip, lymphatic malformation of the face and neck, asymmetry and partial/generalized overgrowth-is a rare vascular disorder of unknown etiology first described in 2008 in six unrelated patients. 4 Only two additional patients have been described. 5, 6 The tissue distribution of the clinical manifestations in patients with CLAPO is similar to other vascular and overgrowth syndromes caused by somatic mutations such as Proteus syndrome caused by activating mutations in AKT1, 7 Sturge-Weber syndrome caused by activating mutations in GNAQ, 8 or PROS (PIK3CA related overgrowth spectrum) caused by activating mutations in PIK3CA. 9 Somatic mosaicism is defined as the presence of more than one clone of cells with different genotypes, all of which are derived from a single cell. Mosaicism can contribute to variable clinical expressivity of a trait due to tissue-specific involvement. Consequently, the phenotypic spectrum of all these vascular and/or segmental overgrowth syndromes is heterogeneous and complex. Somatic mosaicism is a theoretical possibility in CLAPO, and even though it is a clinically well-distinguished syndrome, it shares several clinical manifestations with previously mentioned syndromes as well as with other entities also caused by mutations in genes within the PI3K-Akt-mTOR pathway. Here we tested the hypothesis that CLAPO could be caused by somatic mutations activating this pathway, and we evaluated the natural history and phenotype of CLAPO and its phenotypic overlap with other PI3K-Akt-mTOR entities.
MATERIALS AND METHODS

Patients and samples
The study was performed at the Institute of Medical and Molecular Genetics and the Vascular Anomalies Center at La Paz Hospital, Madrid (Spain). We retrospectively reviewed the clinical characteristics and follow-up of 13 patients diagnosed with CLAPO between February 2007 and March 2017, including the 6 patients reported in the original description of the syndrome. 4 Clinical findings are summarized in Table 1 .
Blood samples were collected from all patients, saliva samples from four patients and affected tissue samples from nine patients ( Table 1) . Affected tissue was defined as any type of vascular malformation obtained as part of the routine treatment, and in the case of cutaneous biopsies, these were obtained in regions with vascular malformation and/or true overgrowth (differentiating it from an asymmetry as a consequence of a vascular malformation). DNA extraction was performed by standard procedures. All studies in this project were approved by the Ethics Committee of the Hospital Universitario La Paz (PI-1919), with informed consent including consent to publish patient photos.
High-throughput sequencing
High-throughput sequencing studies were performed using three distinct custom panels previously available and validated for use in our laboratory. The subsequent analyses of the sequencing data were based on the use of virtual panels (i.e., tiers) with an average expected reading depth of 500 × . The first panel (Tier1: Mosaic panel) included 20 genes known to cause developmental syndromes in the form of somatic mosaicism. The second panel (Tier2: overgrowth, lymphatic and vascular syndromes (OGLYVAS) panel) was composed of 301 genes associated with lymphatic/vascular malformations and overgrowths of vascular origin, including PI3K-AktmTOR pathway genes, as well as 20 genes of the Mosaic panel. The third panel (Tier3: expanded mosaic candidate genes (EMG)) included 1,375 genes, including genes in the OGLYVAS panel. The complete lists of genes can be found in Supplementary Table 1 online.
The three panels were designed, captured, and analyzed with the same tools, protocols, and instruments. The custom panels were designed by using NimbleDesign software (Roche NimbleGen, WI, USA): hg19 NCBI Build 37.1/GRCh37.p13, targeting > 98% of all exons (RefSeq) for these genes. For each sample, paired-end (2 × 150 bp reads) libraries were created according to the standard protocols KAPA HTP Library Preparation Kit for Illumina platforms (Roche Sequencing, CA, USA), SeqCap EZ Library SR (Roche NimbleGen, WI, USA) and NEXTflex-96 Pre Capture Combo Kit (Bioo Scientific, TX, USA) for indexing. The captured DNA samples were sequenced on a NextSeq 500 instrument (Illumina, CA, USA) using a HIGH v2 300 cycles cartridge, according to the standard operating protocol.
Bioinformatics analysis pipeline
Data generated by the NextSeq 500 Desktop Sequencer was analyzed using an in-house bioinformatics pipeline for somatic mosaicism detection. BCL files containing base calls were converted into paired FASTQ files using bcl2fastq-v2.15.0.4 software from Illumina (https://github.com/brwnj/ bcl2fastq) and preprocessing using Trimmomatic 10 for trimming and cropping FASTQ data as well as removing adapters. Subsequently, balanced reads were mapped to hg19/ GRCh37 human genome by using Bowtie2 aligner, 11 and polymerase chain reaction (PCR) duplicate reads were removed using Picard MarkDuplicates (http://broadinstitute. github.io/picard/). A subsequent local realignment and recalibration of reads was done to correct misalignments due to the presence of indels by using Genome Analysis Toolkit RealignerTargetCreator and IndelRealigner, and BaseRecalibrator methods, respectively. Once this preprocessing was achieved, the flowchart depicted in Supplementary  Figure 1 was followed.
The specific approach for mosaic detection included the extraction of the base-pair information for each genomic position from the BAM files using SAMtools mpileup v1. 3 (ref. 12) , facilitating the subsequent single-nucleotide polymorphism/indel calling. The base quality (q value) and mapping quality scores (Q value) were lowered to 0, to characterize mutated alleles amplified in very low proportion and to avoid losing variants in non-unique genomic sequences, since many genes in the capture design have pseudogenes or share high percent identity with other genomic sites.
Variant calling was performed using bcftools v1.3. The low constraints allowed the emergence of many alternate alleles, even though many could be false positives. The strategy of the analysis was to keep all multiallelic sites in the VCF file for later consideration. Some attributes were defined to filter out likely sequencing artifacts or variants with high frequency in samples sequenced in the same run, and others to keep mosaic variants to analyze further on. This was applied in all the samples individually, regardless of the tissue type, generating a corresponding VCF file (see Supplementary  Figure 1a ).
Subsequently, a germ-line versus somatic variant comparison was undertaken by analyzing the tissue and the blood VCF files from the same patient/sample (see Supplementary  Figure 1b ). The contrasting of matched tissue and blood samples was crucial to distinguish somatic from germ-line variants, bringing out low allelic fraction from background noise caused by the high-throughput sequencing error rate. The final files encoded global information about alignments.
Manual filtering was applied to determine the candidate pathogenic variants. The resulting VCF files were manually visualized with the Integrative Genomics Viewer software to verify mutations and correct annotation.
Validation of high-throughput deep sequencing variants (Sanger, pyrosequencing, and droplet digital polymerase chain reaction)
Sanger sequencing was used to confirm variants present in more than 15% of the reads in the deep sequencing data. Standard PCR and Sanger sequencing were performed using the 96-capillary ABI 3730xl ADN analyzer (Applied Biosystems, CA, USA). Long-range PCR and Sanger sequencing were also used to verify chromosomal location in variants found with high identity to another part of the genome. Pyrosequencing primers were designed using PyroMark software, and QIAGEN reagents and the PyroMark Q96 MD instrument (Qiagen, Hilden, Germany) were used according to manufacturer's protocol to confirm mosaic variants in the 5% and 15% read fraction range. Droplet digital polymerase chain reaction (ddPCR), able to detect and quantify somatic mosaic variants at frequencies as low as 0.1%, 13 was used to detect/validate and quantify variants found on deep sequencing studies in less than 5% of reads or variants above 5% of reads but whose confirmation by pyrosequencing was not conclusive. We also used ddPCR to screen for the three common mutations described in PROS (PIK3CA: NM_006218.2: c.1624G > A, p.Glu542Lys; c.1633G > A, p. Glu545Lys; and c.3140A > G, His1047Arg) in all negative samples by high-throughput sequencing. 14 The QX200 Droplet Digital PCR System (Bio-Rad, CA, USA) was used according to the manufacturer´s protocol. Nucleic acid molecules were quantified using a two-color fluorescence detector (FAM channel for mutant allele and VIC channel for wild type) and six assays with well-defined and validated somatic mosaic variants were used as controls to validate the technique.
RESULTS
Clinical features
Longitudinal data for 13 patients with CLAPO was gathered for a total of 70.5 person-years (ranging from 0.8 to 10.2). The mean age at diagnosis was 8.0 years (0.6 to 30.4) and the mean age at the end of this study was 10.4 years (2.2 to 40.5). None of the patients had a relevant family history. Except for one patient of Arab descent whose parents were born in Morocco (P6), all patients in the cohort were Caucasian and had parents from the Iberian Peninsula. The cohort included eight females and five males. Among the main features of CLAPO the only common clinical manifestation was the capillary malformation (CM) of the lower lip (13/13; 100%) ( Figure 1) ; all other features were present at birth or became evident postnatally. The CM of the lower lip was always present in the midline, with a symmetrical distribution, ranging from 2 to 11 cm, with well-defined borders in several patients, and often affecting the portion of the skin under the lip or the intra-oral mucosa. We observed three distinct patterns of midline CM on the lower lip: (i) five patients (P2, P5, P6, P8, P9) had a narrow midline CM with reddish color, (ii) seven patients (P1, P3, P4, P7, P10, P11, P12) had a CM that involved the entire lower lip with a predominant brown/purple color, and (iii) one patient (P13) had a CM including the central inner area of the lower lip without external skin involvement under the vermilion. In our experience, untreated isolated capillary malformations (classically called port-wine stains) evolve by a progressive thickening and darkening of the malformation due to a progressive vessel dilation, which can, in turn, produce skin overgrowth. Nonetheless, we did not observe this type of progression in the complete cohort of 13 patients with CLAPO. However, as some of the patients are very young and have been followed up for a short period of time, thickening and darkening of the CM on the lower lip in these patients cannot be ruled out in the future. Remarkably, what we did observe, based on photographs and information provided by patients and relatives, is a decreased intensity in the CM of the lower lip, usually between months 6 and 18 of age, in four (P1-3, P6) of the six patients followed more than 9 years. While midline CMs of the face are frequently Figure 1 Capillary malformation of the lower lip, the hallmark of CLAPO syndrome, in the 13 patients reviewed. It is constantly a congenital feature, always present in the midline, symmetrical and well defined. There are three patterns: narrow midline capillary malformation (i.e., P6), entire lower lip affected (i.e. P7), and central inner area without external skin involvement (P13).
correlated with lesions of the brain in patients with megalencephaly-capillary malformation syndrome (MCAP), 15 no psychomotor delay or intellectual deficit was apparent in CLAPO patients.
The second major clinical feature was the presence of lymphatic malformations (LMs), observed in 12 of 13 patients (92%). In 10 patients (P3-8, P10-13) the LM involved the lip, oral mucosa, neck, and tongue, seen in 5 of 10 with right sided predominance (P5, P6, P10-12). Another two patients (P1, P2) had unilateral LM on the lower limbs, one of which (P1) was associated with lymphedema. At birth, the tongue had a symmetrical midline combined capillary/lymphatic/venous malformation in 8 of 13 patients (P3-6, P8, P10, P12, P13) with CLAPO, which was mild, well-defined, and affected the tip of the tongue. In 5 of 8 patients (P3-5, P8, P13), the tongue lesions evolved over time, causing growth of the affected area and severe hemorrhagic events with episodes of acute inflammation, triggering and aggravating symptoms. On the other hand, P2 had a left thigh LM that was not noted until 15 years of age, indicating that an apparent absence of congenital LM does not exclude a later onset. Sporadic LMs are rare and arise more often with craniofacial venous malformations. 16 In our cohort LMs of the neck, tongue, and/ or limb were also observed in association with venous malformations in 11 patients (all but P2 and P7), which showed progressive increase in size and in no case involution.
In this cohort the asymmetry in 8 of 13 patients (P4-6, P8, P10-13) actually reflected a direct consequence of the presence of a LM on the face/neck, although in three patients (P1-3) there was a true asymmetric overgrowth with the presence of bony hypertrophy. In addition to the facial asymmetry, P10 had asymmetry caused by left limb undergrowth. P1 had macrodactyly and overgrowth of the right side of the body (Figure 2) , and P2 had a postnatal increase in the length of the left leg. P1 and P2 were initially referred with a diagnosis of Klippel-Trenaunay syndrome.
Recently, P9 suffered a large presacral ganglioneuroma that was successfully resected, and P10 had severe failure to thrive needing gastrostomy. Those findings can eventually expand the phenotype of CLAPO syndrome.
Molecular results
Our main hypothesis was that somatic mutations were the genetic cause of CLAPO. Accordingly, we screened 20 DNA blood/saliva/tissue samples from 9 patients (P1, P2, P4, P6-10, and P13) with CLAPO using custom high-throughput deep sequencing panels including genes associated with vascular malformations and overgrowth, and a custom bioinformatic pipeline for somatic mosaic detection with a tiered analysis approach. Average read depth for Tier1 was 535 × , for Tier2 342 × , and for Tier3 404 × , after removing duplicates. Variants were excluded as disease candidates by their presence in > 0.01 population frequency (1000 Genomes project (http://www.internationalgenome.org/), the National Heart, Lung, and Blood Institute Exome Variant Server (http://evs.gs.washington.edu/EVS), the Exome Aggregation Consortium (ExAC; http://exac.broadinstitute.org)), by pathogenicity predictors, and by using new custom parameters developed here for somatic mosaic detection (AVAF, SampleRun). After filtering, mean variants per sample for Tier1 was 5.2, for Tier2 31.3, and for Tier3 175.6.
Our analysis identified PIK3CA variants in six of nine (66%) patients with CLAPO (P1, P2, P6, P9, P10, and P13). All mutations were somatic missense single-nucleotide variations with a range of mosaicism between 1.26% and 16%. We identified a total of five distinct mutations in PIK3CA (NM_006218.2), including one hotspot mutation (c.1624G > A;p.Glu542Lys); two recurrent, strong (gain of function) mutations (c.3140A > T;p.His1047Leu, c.1258T > C;p. Cys420Arg); one previously described mutation in patients with macrodactyly (c.344G > C;p.Arg115Pro); and one novel somatic PIK3CA mutation (c.248T > C; p.Phe83Ser) not previously described in developmental disorders ( Figure 3) .
All variants detected were confirmed using at least one orthogonal method based on the mosaicism percentage of the alternative allele from the next-generation candidate gene sequencing. None of the mutations detected in the patients were present (by Sanger sequencing) in the blood samples of the patient's parents. Molecular data and variant information were collected in Table 2 . In the affected tissue samples from patients P4, P7, and P8 no mutation was detected. Mean PIK3CA reading depth of 427 × (171-603) for P4, 399 × (151-573) for P7, and 311 × (60-583) for P8 was obtained. 
DISCUSSION
In the present report we describe for the first time the presence of somatic activating PIK3CA mutations in patients with CLAPO, and we report an update of the phenotype and natural history of the syndrome. Somatic mosaic mutations in PIK3CA have been detected in six of nine patients with CLAPO. All mutations were detected in affected tissue, in percentages ranging from 3 to 16%, and in one of the patients (P9) the mutation was also mosaic at a level of 1.26% in a blood sample. All the mutations detected are missense variants, four of which have previously been reported as causing the PROS spectrum 9, 14 and detected in different types of cancer (COSMIC database; http://cancer. sanger.ac.uk/). We also identified a novel PIK3CA mutation (Phe83Ser), not previously described in development disorders, but then again reported in the COSMIC database in three cancer samples.
The family of syndromes caused by activating PIK3CA mutations includes well-known and distinct entities such as MCAP, CLOVES (congenital lipomatous overgrowth, vascular malformations, epidermal nevi, and skeletal/spinal abnormalities), isolated LM, isolated adipose fibrodysplasia, and hemimegalencephaly, among others. 9 In addition to the distribution pattern, some of the syndromes included in PROS have overlapping clinical findings with CLAPO, mainly capillary and lymphatic malformations and segmental overgrowth. However, sharing a common mutated gene does not make their formerly differentiated classification obsolete since it has implications for clinical diagnosis, evolution, and follow-up.
Our findings suggest that somatic activating PIK3CA mutations can be responsible for the combination of capillary, lymphatic, and venous malformation as well as the overgrowth features characteristic of CLAPO syndrome. Given the overlapping phenotypic features between CLAPO and PROS (mainly with MCAP and CLOVES), and the presence of somatic activating PIK3CA mutations, we postulate that CLAPO syndrome might be included into the PROS spectrum.
The multiple or reticulate and diffuse CM present in different parts of the body appear to be similar in both CLAPO and MCAP. However, one of the main clinical manifestations in CLAPO is the CM of the lower lip, a feature that is not considered characteristic of MCAP, in which midline CMs are most frequently described in upper lip, glabella, and philtrum. Anatomically, the differential involvement of the lower lip or the upper lip is distinctive and is relevant as they have distinct embryological origins and clinical implications. The forehead, the dorsum apex of the nose, and the central part of the upper lip derive from the frontonasal prominence, whereas the chin, lower lip, and lower cheek regions derive from the mandibular prominences. These distinct embryological origins might also explain the co-occurrence of brain alterations and CM of the upper lip in MCAP and the absence of neurological involvement in CLAPO.
The second main feature in CLAPO, the LM, is also frequent in CLOVES and facial infiltrating lipomatosis. While 2 of the 13 patients described here had a LM of the legs, this type of malformation occurs in CLAPO more frequently in the cervicofacial region and tongue, where there is a clear nonrandom association with capillary or venous malformations. Venous malformations were not originally described as a main feature in CLAPO, but we now know that they are a rather frequent feature, and it has recently been described that this type of malformation can arise sporadically as a consequence of somatic activating mutations in PIK3CA, 17 which has also been described for isolated LM. 18 Since it is possible that both lymphatic and venous malformations are not apparent congenitally, the presence of CM in the lower lip should make us aware of a possible later appearance of these two types of vascular malformations. This specific and nonrandom combination of vascular malformations highlights the utility of the clinical diagnosis in patients with CLAPO.
Overgrowth is not always evident in CLAPO, as none of the patients had macrocephaly, the involvement was segmental and rarely generalized, and in the case of facial asymmetry it appears to be caused by a vascular component. As with all overgrowth syndromes, it is important to distinguish in CLAPO and PROS what is apparent asymmetry from true overgrowth caused by hyperplasia or hypertrophy. In addition, no patient with CLAPO has lipomatous overgrowth, which is a common feature in the PROS spectrum. In spite of the fact that partial/generalized overgrowth is part of the CLAPO acronym, its low frequency in this cohort of patients suggests that it should not be considered a major clinical criterion for the diagnosis of CLAPO, despite being a frequent (but not mandatory) feature in PROS.
Considering the clinical characteristics and the natural history described in our cohort of patients, CLAPO could be classified as an entity with intermediate severity in the PROS spectrum, sharing characteristics mainly with MCAP and CLOVES, and certainly with isolated forms of lymphatic and venous malformations. One of the major challenges in somatic mosaicism is the detection of altered alleles in low mosaics in affected tissues. Correspondingly, the molecular diagnosis of CLAPO patients is not trivial. One limitation comes from the requirement to obtain affected tissue. Thus, the lack of success detecting PIK3CA mutations in three of nine of the molecularly studied patients with CLAPO does not implicate the absence of mutations in this gene, nor does it exclude the molecular diagnosis of CLAPO.
Another challenge is the bioinformatic method for the detection of somatic mosaicism. There are several computational approaches to detect somatic variants, but they cannot be applied to this problem since the starting data or the genomic landscape is different. Strelka 19 for single-nucleotide variation discovery or Mutect 20 for indel discovery are two of the most used variant callers for somatic variant detection. However, neither of them was developed to detect variants in mosaic disorders. Thanks to the computational approach applied here, we could rescue reads with low mapping quality score due to high percent identity with other genomic regions, and call variants that were present both in somatic and mosaic state.
In conclusion, this study documents the clinical features and natural history in a well-defined cohort of patients with CLAPO, and detected activating PIK3CA mutations in six of nine studied affected tissues. We detected PIK3CA activating variants previously described as causing the PROS spectrum, together with a clinical distribution pattern distinctive of somatic mosaicism, and a constellation of nonrandom clinical manifestations that, although in combination are specific to CLAPO, are also frequent in other syndromes within the PROS spectrum. We conclude that CLAPO belongs to the PROS family of somatic syndromes. In clinical terms, the differences between CLAPO and other PROS spectrum phenotypes demonstrate that the presence of a CM in the upper lip should raise suspicion of possible neurological involvement, whereas the CM in the lower lip may be associated with later occurrence of lymphatic/venous malformations. This could reflect their distinct embryological origin but does not imply that a patient with PROS and without upper lip CM should not be monitored for possible neurological compromise. In diagnostic terms, the approach in CLAPO requires the use of appropriate samples and bioinformatic algorithms, allowing the detection of somatic mosaic variants. Because CLAPO is caused by activating mutations in PIK3CA, affected patients may benefit from inhibitors of this pathway. Therapeutic trials of this disorder should be undertaken.
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